Lynn F, Reed G F, Meade B D
Laboratory of Pertussis, Food and Drug Administration, Rockville, Maryland 20852, USA.
Clin Diagn Lab Immunol. 1996 Nov;3(6):689-700. doi: 10.1128/cdli.3.6.689-700.1996.
Acellular pertussis vaccines are being evaluated in multiple clinical studies, and human immunogenicity data will likely be pivotal in the appraisal of vaccine responses between populations and the responses to different vaccine combinations. Antibody response to pertussis antigens is also used in the diagnosis of pertussis. An international study was designed to assess the comparability of data generated in different laboratories by enzyme-linked immunosorbent assays (ELISAs). Thirty-three participating laboratories were asked to quantitate specific antibody to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), or fimbrial proteins (FIM) in 21 samples. Samples were to be assayed in triplicate in five independent assays by each ELISA routinely performed in the laboratory to assess intra-assay, interassay, and population variability. The mean sample values were used to compare quantitative results among the laboratories. Thirteen of the 32 laboratories which submitted evaluable data for an assay to measure antibodies to PT, 12 of 30 laboratories with assays for FHA, 10 of 17 laboratories with assays for PRN, and 6 of 13 laboratories with assays for FIM maintained a coefficient of variation below 20% for 75% of the samples tested. Assays that measure antibodies to FIM appear to be less precise than the other assays. Precision varied among laboratories that used similar methods. The relative values of intra- and interassay variabilities were not consistent for a given assay within a laboratory, indicating that the sources of these variability components may be unrelated. Precision and agreement appeared less reliable for samples with low antibody levels. Ranking and regression analyses suggest that some laboratories generated comparable quantitative results, although direct comparison or combination of results from different laboratories remains difficult to support. Calibration to the U.S. Reference Pertussis Antisera appears to have been successful at standardizing the results in some laboratories. Statistical analyses are affected by assay precision and are not necessarily reliable sole predictors of biologically relevant differences in quantitative results. If results from different laboratories must be compared, appropriate studies of precision and quantitative agreement should be conducted to support the specific comparisons.
无细胞百日咳疫苗正在多项临床研究中进行评估,人体免疫原性数据可能对评估不同人群之间的疫苗反应以及对不同疫苗组合的反应起着关键作用。对百日咳抗原的抗体反应也用于百日咳的诊断。一项国际研究旨在评估不同实验室通过酶联免疫吸附测定(ELISA)产生的数据的可比性。33个参与实验室被要求对21个样本中的百日咳毒素(PT)、丝状血凝素(FHA)、百日咳杆菌黏附素(PRN)或菌毛蛋白(FIM)的特异性抗体进行定量。每个实验室常规进行的ELISA要在五个独立测定中对样本进行一式三份检测,以评估批内、批间和群体变异性。平均样本值用于比较各实验室之间的定量结果。在提交了用于检测PT抗体的可评估数据的32个实验室中,有13个实验室;在检测FHA的30个实验室中,有12个实验室;在检测PRN的17个实验室中,有10个实验室;在检测FIM的13个实验室中,有6个实验室在75%的检测样本中变异系数保持在20%以下。检测FIM抗体的测定似乎不如其他测定精确。使用类似方法的实验室之间精度有所不同。对于一个给定的测定,批内和批间变异的相对值在一个实验室中并不一致,这表明这些变异成分的来源可能无关。对于抗体水平低的样本,精度和一致性似乎不太可靠。排名和回归分析表明,一些实验室产生了可比的定量结果,尽管直接比较或合并不同实验室的结果仍然难以支持。校准到美国参考百日咳抗血清似乎在一些实验室成功地使结果标准化。统计分析受测定精度影响,不一定是定量结果中生物学相关差异的可靠唯一预测指标。如果必须比较不同实验室的结果,应进行适当的精度和定量一致性研究以支持具体比较。